Adage Capital Partners’s Aldeyra Therapeutics ALDX Stock Holding History

Adage Capital Partners’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,000,000	Closed	-$5.81M	–	725
2019 Q4	$5.81M	Sell	1,000,000 -418,822	-30%	-$2.42M	0.01%	594
2019 Q3	$7.48M	Buy	1,418,822 +250,000	+21%	+$1.35M	0.02%	577
2019 Q2	$7.01M	Buy	1,168,822 +50,000	+4%	+$376K	0.02%	573
2019 Q1	$10.1M	Buy	1,118,822 +573,822	+105%	+$4.88M	0.03%	525
2018 Q4	$4.52M	Buy	545,000 +154,000	+39%	+$1.58M	0.01%	613
2018 Q3	$5.4M	Sell	391,000 -359,000	-48%	-$2.91M	0.01%	632
2018 Q2	$5.96M	Hold	750,000	–	–	0.01%	638
2018 Q1	$5.63M	Buy	750,000 +57,000	+8%	+$433K	0.01%	634
2017 Q4	$4.71M	Sell	693,000 -57,000	-8%	-$375K	0.01%	630
2017 Q3	$5.4M	Buy	750,000 +275,000	+58%	+$1.44M	0.01%	619
2017 Q2	$2.21M	Hold	475,000	–	–	0.01%	661
2017 Q1	$2.38M	Buy	+475,000	New	+$2.45M	0.01%	657

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

Adage Capital Partners's ALDX Position: Q1 2020 in Review

Adage Capital Partners sold out of Aldeyra Therapeutics (ALDX) in Q1 2020, closing a stake of 1,000,000 shares — an estimated $5.81M sold.

Adage Capital Partners first reported a position in ALDX in Q1 2017 and held it in 12 quarters. The position peaked at $10.1M in Q1 2019. 72 funds tracked by Wall St. Rank hold ALDX as of Q1 2020.

Adage Capital Partners reported no remaining Aldeyra Therapeutics position as of Q1 2020 after selling out during the quarter.
Adage Capital Partners sold 1,000,000 Aldeyra Therapeutics shares in Q1 2020, an estimated $5.81M.
Adage Capital Partners first reported a position in Aldeyra Therapeutics in Q1 2017 and held it in 12 quarters.
Adage Capital Partners's Aldeyra Therapeutics position peaked at $10.1M in Q1 2019.
72 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2020.

Based on Adage Capital Partners's 13F filing for Q1 2020, filed 15 May 2020.